Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class ...

The resulting 124 I-evuzamitide (previously known as AT-01) has been shown to detect amyloidosis in organs like the heart, liver, and kidney. Previous work also showed that this amyloid-specific PET ...

The FDA has set a PDUFA target action date of March 29, 2026. “The development of LNTH-2501 underscores our commitment to expanding access to high-quality diagnostic solutions in oncology,” said Brian ...

Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver ...

Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight ...

Enigma Biomedical USA (EB USA) today announced that the Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for MK-6240 (florquinitau F-18), their Tau Positron Emission ...

The NDA submission is supported by data from two pivotal Phase 3 clinical trials, which evaluated MK-6240’s performance in detecting tau pathology in early Alzheimer’s disease. These studies met their ...

By rethinking operational models, radiopharma leaders can mitigate risks, increase efficiency and ensure reliable access to ...

The panel asserts that antibody-based radiotracers exhibit lower renal clearance, thereby improving visualization of renal masses. It emphasizes that TLX250-CDx PET "appears to be a well-tolerated and ...

One leading broker thinks this stock could be a cheap buy at current levels. The post Why Telix shares could rise almost 40% ...

Iran has ranked among the world’s top three radiopharmaceutical producers, providing isotopes to domestic centres and ...

The new £360,000 fee-for-service development contract is to develop Optimer® binders as targeted radiopharmaceuticals with potential applications in therapeutics. Aptamer retains rights for future ...